Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of March 31, 2025, the number of shareholders for the company increased to 47,404, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] Group 2 - The company's price-to-earnings (PE) ratio (TTM) is -14.05, and the price-to-book (PB) ratio is 19.13, with a total market capitalization of 2.183 billion yuan [2] - The industry average PE ratio is 38.66, while the industry median is 43.32, indicating that the company is significantly below the industry average in terms of valuation metrics [2] - Comparatively, other companies in the industry have varying PE ratios, with some companies like RunDa Medical showing a PE ratio of -296.69, indicating a wide range of performance and valuation within the sector [2]

Group 1 - The core viewpoint of the articles highlights the advancement in the diagnosis and treatment of amblyopia through genetic testing and innovative therapies, particularly the use of perceptual learning training [1][2] - The introduction of genetic testing allows for more accurate diagnosis by identifying pathogenic gene mutations, which can lead to more effective treatment strategies [1][2] - The perceptual learning training technique utilizes the brain's plasticity to improve visual processing pathways, enhancing treatment outcomes for patients with amblyopia and related conditions [2] Group 2 - He Eye Hospital has been committed to technological innovation and collaboration with strategic partners to advance eye health, focusing on gene therapy, stem cell regeneration, and smart ophthalmic equipment [3] - The company aims to integrate cutting-edge technology with healthcare data to create a comprehensive ecosystem for eye health, aligning with national health strategies [3] - The strategic goal of He Eye Hospital is to build a "Smart City of Light," leveraging its unique advantages in the eye health industry [3]

庞继景教授指出，基因检测正逐步成为儿童视力评估常规项目，结合屈光矫正形成多维度干预体系。这 种转变使弱视治疗成功率提升30%，并为遗传性眼病患者抢抓3-12岁视觉发育黄金期。 作为国内眼健康全产业链平台，何氏眼科持续深耕基因治疗、干细胞再生医学及智能设备数据应用三大 领域。在"十四五"眼健康规划推动下，企业正通过科技创新践行"智慧光明城"战略目标，为健康中国建 设注入新动能。（燕云） （文章来源：证券时报网） 近日，何氏眼科(301103)在儿童弱视诊疗领域取得突破性进展。通过融合基因检测与视知觉学习训练技 术，成功将传统弱视诊疗模式推向精准化新阶段。 在临床实践中，遗传眼病首席科学家庞继景教授团队接诊的9岁高度近视患儿案例引发关注。通过 OPN1LW基因检测，团队发现其近视实为遗传性视网膜疾病早期表现，颠覆了传统"弱视"诊断结论。基 于此，团队创新采用视知觉学习训练：通过Gabor视标刺激视觉皮层神经可塑性，经4个月家庭化训练， 患儿右眼视力从0.7提升至0.9，屈光度发展得到有效控制。 这项技术的突破性在于构建"基因筛查-大脑重塑"双轨诊疗体系。通过排除致病基因变异确保诊断精准 性，再运用视知觉训练激活视 ...

Core Viewpoint - The company, Liaoning He Eye Hospital Group Co., Ltd., has announced its 2024 annual equity distribution plan, which includes a cash dividend of 1.5 RMB per 10 shares for all shareholders, excluding repurchased shares [2][6]. Summary by Sections Equity Distribution Plan - The total number of shares eligible for the cash dividend is 155,303,752 shares after excluding 2,722,719 shares held in the repurchase account [2][6]. - The total cash dividend amount to be distributed is 23,295,562.80 RMB (including tax) [2][6]. Dividend Calculation - The cash dividend per share, after considering the total share capital including repurchased shares, is calculated as 1.474155 RMB per share [2][11]. - The reference price for ex-dividend trading will be adjusted by subtracting the cash dividend per share from the closing price on the last trading day before the ex-dividend date [2][11]. Shareholder Meeting Approval - The equity distribution plan was approved at the shareholder meeting held on May 22, 2025, and the implementation will occur within two months of this approval [4][5]. Key Dates - The record date for the equity distribution is set for May 30, 2025, and the ex-dividend date is June 3, 2025 [7]. Eligible Shareholders - The distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [8]. Repurchased Shares - Shares held in the company's repurchase account will not participate in this equity distribution [9].

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 1.5 RMB per 10 shares for all shareholders, excluding repurchased shares [1][2]. Group 1: Dividend Distribution Details - The total number of shares eligible for the cash dividend is 155,303,752 shares after excluding 2,722,719 repurchased shares, resulting in a total cash dividend payout of 23,295,562.80 RMB (including tax) [1][2]. - The cash dividend per share, calculated based on the total share capital, is approximately 1.474155 RMB per share [1][4]. - The dividend distribution will not include capital reserve transfers to increase share capital or stock bonuses [2][3]. Group 2: Key Dates - The record date for the dividend distribution is set for May 30, 2025, and the ex-dividend date is June 3, 2025 [2][3]. Group 3: Taxation and Adjustments - The company will not withhold individual income tax for certain shareholders, with tax obligations calculated based on the holding period upon stock transfer [2][4]. - The reference price for the ex-dividend will be adjusted by subtracting the cash dividend per share from the closing price on the last trading day before the ex-dividend date [4].

Core Insights - The collaboration between Carl Zeiss and He Eye Hospital marks the introduction of advanced refractive surgery technology in Northeast China, providing a revolutionary "10-second rapid vision correction" experience for myopic patients [1][3] - The new generation of all-laser technology, VISUMAX 800 and SMILE pro, offers significant improvements in surgical efficiency, precision, and safety, enhancing patient comfort during procedures [1][2] Group 1: Technology and Innovation - The VISUMAX 800 technology reduces single-eye scanning time from 23 seconds to under 10 seconds, improving efficiency by 36% and minimizing patient discomfort during surgery [1] - The technology features CentraLign intelligent navigation and OcuLign eye rotation compensation systems, which track eye movements in real-time and reduce postoperative residual astigmatism [1] - The dual robotic arm design ensures stable and reliable operation during surgery, enhancing overall safety [1] Group 2: Clinical Application and Experience - He Eye Hospital successfully completed its first SMILE pro surgery on May 15, with the first patient expressing high satisfaction with the quick and nearly painless procedure [2] - The hospital has established a comprehensive service management system, ensuring standardized operations and clinical experience to support the application of this breakthrough technology [2] - He Eye Hospital has been recognized as one of the first high-end refractive surgery institutions in China, emphasizing its commitment to technological innovation and patient-centered care [2] Group 3: Financial Services and Accessibility - The launch of the "Bright Future" financial service plan in collaboration with Industrial Bank provides low-interest installment credit services to myopic patients, making advanced technology more accessible [2]

Core Viewpoint - The company aims to focus on organic growth while completing its mission of external mergers and acquisitions, with a strategic emphasis on the "1+8+N" model and the integration of artificial intelligence in ophthalmology services [2][3]. Financial Performance - In 2024, the company reported a revenue of 20.983 billion yuan, a year-on-year increase of 3.02%, and a net profit exceeding 3.5 billion yuan, growing by 5.87% [2]. - In Q1 2025, the company returned to high growth, achieving a revenue of 6.026 billion yuan, up 15.97%, and a net profit of 1.05 billion yuan, increasing by 16.71% [2]. Strategic Development - The "1+8+N" strategy has been fully implemented, with significant progress in establishing regional ophthalmology centers across China, including flagship hospitals in Shanghai and Nanning [3]. - The company has expanded its operational footprint to 352 ophthalmology hospitals and 229 outpatient departments, enhancing its chain operation advantages [3]. Digital Transformation - The company has made notable advancements in digital ophthalmology and AI applications, collaborating with the Chinese Academy of Sciences to explore the establishment of "Aier AI Eye Hospital" [4]. - The company launched its self-developed ophthalmology vertical model AierGPT and the digital persona "Eyecho," enhancing service efficiency and patient experience [4]. Social Responsibility - The company integrates public welfare into its development strategy, conducting vision health screenings and education in schools and rural areas, and has donated 217 million yuan in 2024 [5]. - The company has established a stable cash dividend system, with a total cash dividend of approximately 1.487 billion yuan for 2024, maintaining a consistent dividend payout for 15 years [5].

Core Insights - The valuation adjustment of commercial real estate in core cities has led to increased interest in high-quality properties, with many publicly listed companies accelerating the acquisition of office buildings and R&D spaces to optimize asset structures and reduce long-term operational costs [1] Group 1: Company Acquisitions - Several listed companies have announced the purchase of office buildings and R&D spaces this year, primarily in first-tier and key second-tier cities such as Shenzhen, Shanghai, Beijing, and Zhuhai [1] - Aier Eye Hospital announced the acquisition of a 60% stake in Shenzhen Guangsheng Digital Technology Co., including the "Guangsheng Science and Technology Innovation Building" for approximately 650 million yuan, to be used as a long-term medical facility [2] - Lexin Technology plans to purchase a technology office building in Shanghai for about 436 million yuan to expand its R&D center, addressing space constraints and rising rental costs [2] - Founder Securities acquired an office property in Shanghai for over 100 million yuan to enhance its market penetration in East China [3] - Light Media announced a 1.22 billion yuan investment to acquire a 100% stake in a company to secure office space in Beijing, aligning with its strategic growth plans [3] Group 2: Market Trends - The current period of commercial real estate valuation adjustment has led to a decline in rental and sale prices for high-quality properties in core cities, making it more feasible for companies to upgrade their self-owned office properties [4] - The trend of companies purchasing properties is concentrated in core business districts or emerging industrial parks, indicating a rational approach to asset allocation with a focus on long-term usage value [4] - The stable operation of core businesses and sufficient cash flow support the strategic acquisition of office buildings, signaling a positive outlook for the market [5] - With the continuous decline in domestic benchmark interest rates, many properties are providing stable cash flows, making them more attractive than various financial products [5]

Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of the first quarter of 2025, the company reported revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] - The company's stock closed at 4.24 yuan, up 2.17%, with a latest price-to-book ratio of 19.27, marking a new low in 40 days, and a total market capitalization of 2.198 billion yuan [1] Group 2 - The company has three institutional investors holding a total of 137.3928 million shares, with a total market value of 541 million yuan [1] - The company's price-to-earnings ratio (TTM) is -14.15, while the industry average is 38.49, indicating a significant disparity [2] - The company's market capitalization stands at 2.198 billion yuan, compared to the industry median of 5.270 billion yuan [2]

Core Viewpoint - Chengdu Puri Eye Hospital Group Co., Ltd. is a leading provider of comprehensive eye care services in China, focusing on innovation and professional expertise to build a competitive advantage in the ophthalmology sector [2]. Group 1: Company Overview - The company specializes in diagnosing, treating, and providing healthcare services for various eye diseases, including refractive surgery, cataracts, and other ophthalmic conditions [2]. - Puri Eye has established a strong brand identity based on "professionalism, innovation, and responsibility," and has created a competitive edge through a nationwide chain of eye hospitals [2]. - The company employs a "full-cycle eye health management" approach, integrating renowned medical experts and cutting-edge technology to enhance service quality [2]. Group 2: Financial Performance - In the first quarter of 2025, the company reported a revenue of 742 million yuan, representing a year-on-year increase of 9.82% [3]. - The net profit for the same period was approximately 27.28 million yuan, showing a significant year-on-year growth of 61.18% [3]. - The gross profit margin stood at 39.34%, indicating a healthy profitability level compared to industry peers [3]. Group 3: Market Position - As of the latest data, Puri Eye's market capitalization is approximately 6.178 billion yuan, with a price-to-earnings (PE) ratio of 67.51 [3]. - The company has a price-to-book (PB) ratio of 2.89, which is competitive within the industry [3]. - The company is positioned favorably against industry averages, with its PE and PB ratios reflecting strong market confidence [3].